

TSC22D3 Antibody (Center) Blocking Peptide Synthetic peptide Catalog # BP16682c

Specification

TSC22D3 Antibody (Center) Blocking Peptide - Product Information

Primary Accession

<u>Q99576</u>

TSC22D3 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 1831

Other Names

TSC22 domain family protein 3, DSIP-immunoreactive peptide, Protein DIP, hDIP, Delta sleep-inducing peptide immunoreactor, Glucocorticoid-induced leucine zipper protein, GILZ, TSC-22-like protein, TSC-22-related protein, TSC-22R, TSC22D3, DSIPI, GILZ

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

TSC22D3 Antibody (Center) Blocking Peptide - Protein Information

Name TSC22D3 (HGNC:3051)

Function

Protects T-cells from IL2 deprivation-induced apoptosis through the inhibition of FOXO3A transcriptional activity that leads to the down-regulation of the pro-apoptotic factor BCL2L11 (PubMed:15031210). In macrophages, plays a role in the anti- inflammatory and immunosuppressive effects of glucocorticoids and IL10 (PubMed:12393603). In T-cells, inhibits anti-CD3-induced NFKB1 nuclear translocation and thereby NFKB1 DNA-binding activities (PubMed:11468175). In vitro, suppresses AP-1 transcription factor complex DNA-binding activities (By similarity).

Cellular Location

[Isoform 1]: Cytoplasm {ECO:0000250|UniProtKB:Q9Z2S7}. Nucleus {ECO:0000250|UniProtKB:Q9Z2S7} Note=Localization depends on differentiation status of myoblasts (By similarity). In undifferentiated myoblasts; localizes to the cytoplasm, but in differentiating myoblast; localizes to the nucleus (By similarity). {ECO:0000250|UniProtKB:Q9Z2S7}



Tissue Location

Ubiquitously expressed, including in the fetal brain and liver (PubMed:26752201). Expressed in brain, lung, spleen and skeletal muscle (PubMed:11313722, PubMed:12393603). Lower levels detected in heart and kidney (PubMed:11313722, PubMed:12393603). Not detected in the pancreas (PubMed:11313722). In non-lymphoid tissues, in the absence of inflammation, the major source of constitutive expression is the macrophage lineage (PubMed:12393603). Also expressed in cells from different hemopoietic cell lineages, including bone marrow cells, CD34+ stem cells, mature B- and T-cells, monocytes and granulocytes (PubMed:11313722). Down-regulated in activated macrophages from inflammatory lesions of delayed-type hypersensitivity (DTH) reactions, such as in tuberculosis and in Crohn disease, whereas in Burkitt lymphoma, persists in macrophages involved in the phagocytosis of apoptotic malignant cells (PubMed:12393603)

TSC22D3 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

TSC22D3 Antibody (Center) Blocking Peptide - Images

TSC22D3 Antibody (Center) Blocking Peptide - Background

The protein encoded by this gene shares significantsequence identity with the murine TSC-22 and Drosophila shs, bothof which are leucine zipper proteins, that function astranscriptional regulators. The expression of this gene isstimulated by glucocorticoids and interleukin 10, and it appears toplay a key role in the anti-inflammatory and immunosuppressive effects of this steroid and chemokine. Transcript variants encoding different isoforms have been identified for this gene. [provided byRefSeq].

TSC22D3 Antibody (Center) Blocking Peptide - References

Latre de Late, P., et al. J. Biol. Chem. 285(8):5594-5605(2010)Lekva, T., et al. J. Clin. Endocrinol. Metab. 95(1):246-255(2010)Soundararajan, R., et al. Proc. Natl. Acad. Sci. U.S.A. 106(19):7804-7809(2009)Zhang, X.H., et al. Clin. Exp. Allergy 39(5):647-654(2009)Redjimi, N., et al. Mol. Cancer 8, 83 (2009) :